FierceBiotech 2026年3月2日 Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
FierceBiotech 2026年3月2日 TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio
FierceBiotech 2026年3月2日 Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
FierceBiotech 2026年3月2日 United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
FierceBiotech 2026年3月2日 UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
FierceBiotech 2026年3月2日 Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock
FierceBiotech 2026年3月2日 Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
FierceBiotech 2026年2月28日 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
FierceBiotech 2026年2月27日 Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
FierceBiotech 2026年2月27日 Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
FierceBiotech 2026年2月27日 FDA slams ExThera with warning letter over controversial blood filter device